hrt and tirzepatide New research from a Mayo Clinic–led study suggests that postmenopausal women using menopause hormone therapy may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication for overweight obesity. In Unlocking the potential of menopause

Allow refrigerated vials to reach room temperature for 15 minutes before drawing doses

Although diabetic patients and individuals with vascular disease face a higher baseline risk, anyone experiencing sudden changes in vision should seek immediate medical attention to protect their eye health and identify potential underlying conditions affecting the body

Is the $499 Ozempic and Wegovy offer available in every state

Additionally, tirzepatide led to greater weight reduction than semaglutide

GLP-1 (Glucagon-Like Peptide-1) helps: Increase satiety (feeling full) Reduce appetite Improve insulin response This is the primary mechanism used in earlier weight loss injections

Switching at higher body weights Patients with a BMI above 40 or body weight above 300 pounds may respond differently to the standard titration protocol